Overview
Cartalax is an ultrashort peptide motif (Ala‑Glu‑Asp; “AED”) studied for its potential to support cartilage health through fibroblast activity and extracellular matrix regulation in laboratory models.
What It Is
Cartalax represents a “cartilage-associated peptide motif” that researchers have investigated in vitro. The compound utilizes peptide transporters (POT/LAT families) and demonstrates cell-penetrating properties in model systems. Research suggests potential applications in supporting connective tissue health through gene expression modulation.
Proposed Mechanism
In published studies, AED-related peptides have been associated with:
– Increased collagen I expression in fibroblasts
– Activation of SIRT-family pathways in aging cell models
– Modulation of genes linked to extracellular matrix turnover
– Support for cellular stress response pathways
Reconstitution Protocol
Standard Approach (3.0 mL = ~6.67 mg/mL)
1. Using aseptic technique, draw 3.0 mL bacteriostatic water
2. Insert needle through vial stopper; allow diluent to run slowly down the vial wall (avoid foaming)
3. Gently swirl/roll until fully dissolved—do not shake
4. Label vial and maintain sterility; avoid repeated freeze-thaw cycles
5. Protect from light exposure when practical
Dosing Schedule
Route & Frequency: Subcutaneous, once daily
Gradual Titration Framework (8-12 weeks):
| Week | Daily Dose | Units (U-100) | Volume (mL) |
|---|---|---|---|
| 1–2 | 2,000 mcg | 30 units | 0.30 mL |
| 3–4 | 3,000 mcg | 45 units | 0.45 mL |
| 5–6 | 4,000 mcg | 60 units | 0.60 mL |
| 7–12 | 5,000 mcg | 75 units | 0.75 mL |
Measurement Math: At 6.67 mg/mL concentration, 1 unit on a U-100 insulin syringe equals approximately 66.7 mcg.
Injection Technique
– Clean vial stopper and injection site with alcohol; allow to dry
– Pinch a skinfold; insert needle at approximately 45° angle into subcutaneous tissue
– No aspiration required for subcutaneous administration
– Inject slowly and steadily
– Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
– Use new sterile syringe for each injection; dispose in sharps container
Supplies Needed (8-Week Protocol Example)
| Supply | Quantity |
|---|---|
| Cartalax 20 mg vials | ~10 |
| U-100 insulin syringes | 56 |
| Bacteriostatic water (10 mL bottles) | 3 |
| Alcohol swabs | 112 |
Storage & Handling
– Maintain sterility throughout preparation and administration
– Minimize temperature cycling and repeated freeze-thaw exposure
– Protect from direct light when practical
– Follow local institutional guidelines for storage and beyond-use dating
– Document dose and site rotation for consistency
Potential Benefits (Literature-Based)
Research in model systems suggests:
– Support for collagen synthesis and matrix integrity
– Activation of cellular maintenance pathways (SIRT-family)
– Potential application to chondrogenesis and osteochondral strategies
– General fibroblast activity enhancement
Side Effects & Tolerability Notes
– Transient local effects possible: redness, itching, or injection-site tenderness
– Volume management and proper technique reduce discomfort (≤0.75 mL per site recommended)
– General subcutaneous administration considerations apply
– No systematic human safety data specific to Cartalax published to date
Important Notes
– Research Only: This protocol is educational and intended for research contexts only
– Not Medical Advice: This content does not constitute diagnosis, treatment, or medical guidance
– Consult Professionals: Always work with qualified healthcare providers before beginning any research protocol
– Limited Human Data: Published human posology specific to Cartalax is limited; recommendations prioritize measurement clarity and tolerability
– Site Rotation: Minimize irritation through consistent site rotation and documentation
– Sterile Technique: Maintain aseptic conditions throughout preparation and administration
Supporting Evidence Notes
The framework above aligns with:
– Recognized subcutaneous administration guidelines (CDC/WHO/NCBI resources)
– General pharmacologic volume tolerability parameters for SC injection
– Published literature on ultrashort peptide transport and cellular mechanisms
– Cartilage-related peptide research contexts
Disclaimer: This content is educational only and does not constitute medical advice, diagnosis, or treatment recommendation.